期刊文献+

UPLC-MS/MS法检测大鼠血浆中伊马替尼的浓度及其药代动力学研究 被引量:1

Determination of Imatinib in Rat Plasma by UPLC-MS / MS and Its Application to Pharmacokinetic Study
原文传递
导出
摘要 目的建立快速检测大鼠血浆中伊马替尼浓度的UPLC-MS/MS方法。方法用乙腈沉淀血浆蛋白的方法处理,运用三重四级杆液质联用仪,色谱柱为CORTECS^(TM)UPLC~C18柱(100 mm×2.1 mm,1.6μm);流动相为乙腈-水(含0.1%甲酸),梯度洗脱,流速为0.4 ml·min^(-1),柱温40℃,内标为阿帕替尼;质谱条件:电喷雾离子化源(ESI),正离子检测模式。结果伊马替尼的保留时间为0.94 min,线性范围为10~1600 ng·ml^(-1)(r=0.9991),最低定量限为2 ng·ml^(-1),回收率为73.91%~77.88%,日内、日间RSD均<10%。结论该法准确可靠,操作简便,重复性好,适于检测大鼠血浆中伊马替尼的浓度。 Objective To establish an ultra performance liquid chromatography-tandem quadrupole mass spectrometry method for the determination of imatinib in rat plasma. Methods A CORTECS^TMUPLC^(R)C_(18)( 100 mm ×2. 1 mm,1. 6 μm) column was used as the stationary phase at 40 ℃. The mobile phase consisted of acetonitrile and water( containing 0. 1% formic acid) at gradient elution pumped at a flow rate of 0. 4 ml·min^-1. The analytes were detected on a triple-quadrupole mass spectrometer equipped with an ESI interface in a positive mode. Results The retention time of imatinib was 0. 94 min. Excellent linear calibration curves of imatinib were obtained in the concentration range of 10- 1600 ng·ml^-1( r =0. 9991). The lower limit of quantification of imatinib was 2 ng·ml^-1 while the average recovery was 73. 91%- 77. 88%. The intra and inter day six standard deviations were below 10%. Conclusion This method is accurate,simple and suitable for the determination of imatinib in rat plasma.
出处 《解放军药学学报》 CAS CSCD 2015年第6期473-476,480,共5页 Pharmaceutical Journal of Chinese People's Liberation Army
基金 国家自然科学基金青年科学基金项目 No.81401558
关键词 伊马替尼 血药浓度 UPLC-MS/MS imatinib plasma concentration UPLC-MS /MS
  • 相关文献

参考文献20

二级参考文献130

  • 1吕晓毅,朱娟,李艳,卢香兰,李霞,何娟,翟明.伊马替尼治疗Ph阳性进展期慢性粒细胞白血病[J].中国新药与临床杂志,2005,24(7):542-546. 被引量:2
  • 2Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res, 2002, 8: 935-942.
  • 3Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood, 2008, 111: 1039-1043.
  • 4Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica, 2009, 94: 205-212.
  • 5Druker BJ, Guilhot F, O" Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006, 355: 2408-2417.
  • 6Bianchini M, De Brasi C, Gargallo P, et al. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients. Eur J Haematol, 2008.
  • 7Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 2001, 344: 1031-1037.
  • 8Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL- positive cells. Blood, 1997, 90: 3691-3698.
  • 9Colombat M, Fort M P, Chollet C, et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica, 2006, 91: 162-168.
  • 10Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 2007, 109: 3496-3499.

共引文献39

同被引文献17

  • 1涂厉标,祝永明.HPLC法同时测定人血清中苯巴比妥、苯妥英和卡马西平的浓度[J].中国药师,2005,8(11):934-936. 被引量:7
  • 2Panomvana D, Traiyawong T, Towanabut S. Effect of CYP3A5 geno- types on the pharmacokinetics of carbamazepine when used as mono-therapy or co-administered with phenytoin, phenobarbital or valproic acid in Thai patients[J]. J Pharm Pharm Sci, 2013,16(4) :502-510.
  • 3Battino D, Croci D, Rossini A, et al. Serum carbamazepine concentra- tions in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data [ J ]. Epilepsia, 2003, 44 (7) :923-929.
  • 4Roveri FL, Paranhos BA, Yonamine M. Determination of phenobarbi- tal in hair matrix by liquid phase microextraction (LPME) and gas chromatography-mass spectrometry (GC-MS) [ J ]. Forensic Sci htt, 2015, 265:75-80.
  • 5Currie RA, Peffer RC, Goetz AK, et al. Phenobarbital and propicon- azole toxicogenomic profiles in mice show major similarities consistent with the key role that constitutive androstane receptor (CAR) activa- tion plays in their mode of action[J]. Toxicology,2014, 321:80-88.
  • 6Teo HL, Wong L, Liu Q, et al. Simple and accurate measurement of carbamazepine in surface water by use of porous membrane-protected micro-solid-phase extraction coupled with isotope dilution mass spec- trometry[ J ]. Anal Chim Acta ,2016,912:49-57.
  • 7E1Hamd MA, Wada M, Ikeda R, et al. Validation of an LC-MS/MS Method for the Determination of Propofol, Midazolam, and Carbamas- epine in Rat Plasma: Application to Monitor Their Concentrations Fol- lowing Co-administration[ J ]. Biol Pharm Bull, 2015, 38 ( 8 ) : 1250- 1253.
  • 8de Almeida CA, Oliveira MS, Mallmann CA, et al. Determination of the psychoactive drugs carbamazepine and diazepam in hospital effluent and identification of their metabolites[ J]. Environ Sei Pollut Res lnt, 2015, 22(21 ) :17192-17201.
  • 9陈冰,蔡卫民.抗癫痫药物的治疗药物监测与个体化用药进展(上)[J].中国药师,2010,13(2):197-199. 被引量:12
  • 10陈冰,蔡卫民.抗癫痫药物的治疗药物监测与个体化用药进展(下)[J].中国药师,2010,13(2):200-202. 被引量:4

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部